Effects of 12-O-tetradecanylphorbol 13-acetate (TPA) on a clonal human teratoma-derived embryonal carcinoma cell line.
The response of a human embryonal carcinoma cell line LICR LON HT39/7 to 12-O-tetradecanylphorbol 13-acetate (TPA) has been studied. Cells treated with 5 ng/ml of TPA undergo marked morphological changes, becoming flattened with nuclear enlargement and developing a grainy and often vacuolated cytoplasm. Parallel changes in the cell surface phenotype of the treated cells also occur. These include the appearance of membrane fibronectin, the embryonic antigen SSEA-1, and a glycoprotein antigen recognised by a monoclonal antibody. There is also increased expression of histocompatibility antigens. Other membrane molecules, such as peanut agglutinin receptor(s) and a 200 000 membrane glycoprotein appear to be removed from the membrane following TPA treatment. The high levels of alkaline phosphatase normally present in LICR LON HT39/7 are also reduced by TPA. Changes in the ultrastructure of the cells have also been observed, such as increases in nuclear complexity and in the number of intermediate filaments in the treated cells. This latter observation has been confirmed by immunofluorescent staining of the cells for prekeratins, which show an extensive network following the addition of TPA, but not before. 2-Dimensional gel electrophoresis of the proteins synthesized by LICR LON HT39/7 before and after addition of TPA has shown that there are a number of alterations in the proteins synthesised by the treated cells. Furthermore, immunoprecipitation of the culture supernatants from these cells has shown that TPA induces the synthesis and secretion of fibronectin. The alterations in the phenotype of LICR LON HT39/7 induced by TPA are irreversible and the altered cells, whilst they stop dividing, can be maintained for at least three weeks in culture. The analogue of TPA 12-O-tetradecanylphorbol 13-myristate does not produce the effects described above.
D000954:Antigens, Surface / Q000032:analysis; D002448:Cell Adhesion / Q000187:drug effects; D002460:Cell Line; D002467:Cell Nucleus / Q000648:ultrastructure; D006063:Chorionic Gonadotropin / Q000096:biosynthesis; D002999:Clone Cells; D003599:Cytoskeleton / Q000648:ultrastructure; D005353:Fibronectins / Q000096:biosynthesis; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D008565:Membrane Proteins / Q000032:analysis; D009363:Neoplasm Proteins / Q000096:biosynthesis; D009940:Organoids / Q000648:ultrastructure; D010704:Phorbols / Q000494:pharmacology*; D013724:Teratoma / Q000378:metabolism / Q000648:ultrastructure; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology*; D000509:alpha-Fetoproteins / Q000096:biosynthesis
D000954:Antigens, Surface; D006063:Chorionic Gonadotropin; D005353:Fibronectins; D006680:HLA Antigens; D008565:Membrane Proteins; D009363:Neoplasm Proteins; D010704:Phorbols; D000509:alpha-Fetoproteins; D013755:Tetradecanoylphorbol Acetate